期刊文献+

失分化型甲状腺癌再分化研究进展 被引量:4

Research progress of redifferentiation of dedifferentiated thyroid carcinoma
下载PDF
导出
摘要 甲状腺碘代谢相关基因是甲状腺癌分化的重要标志。分化型甲状腺癌由于失去或下调一系列碘代谢相关基因的表达而发生失分化,导致癌细胞丧失对放射性碘(^(131)I)的摄取能力。因此,再分化的研究对甲状腺癌^(131)I治疗具有重要意义。研究证实,BRAF基因突变与甲状腺乳头状癌的失分化现象密切相关。文章就通过上调甲状腺碘代谢相关基因表达和抑制BRAF基因突变而使失分化型甲状腺癌再分化的研究进展作一综述。 Thyroid iodide-metabolizing genes are established markers for differentiation of thyroid carcinoma. The loss or down-regulation of iodide-metabolizing genes represents progression of dedifferentiation of differentiated thyroid carcinoma, which results in the disability to take up and accumulate radioiodine (^131 I). Therefore, the research of redifferentiation is important for ^131I therapy of thyroid carcinoma. BRAF gene mutation has been confirmed to be closely related to the dediffercntiation of papillary thyroid carcinoma. The research progress of redifferentiation of dedifferentiated thyroid carcinoma by up-regulation of thyroid iodide-metabolizing genes expression and suppression of BRAF mutation is reviewed in this paper.
作者 侯莎莎 王辉
出处 《上海交通大学学报(医学版)》 CAS CSCD 北大核心 2010年第3期275-278,共4页 Journal of Shanghai Jiao tong University:Medical Science
关键词 失分化型甲状腺癌 放射性碘 甲状腺碘代谢相关基因 BRAF基因突变 dedifferentiated thyroid carcinoma radioiodine thyroid iodide-metabolizing gene BRAF gene mutation
  • 相关文献

参考文献36

  • 1Coelho SM, de Carvalho DP, Vaisman M et al. New perspectives on the treatment of differentiated thyroid cancer[ J ]. Arq Bras Endocrinol Metabol, 2007, 51(4): 612-624.
  • 2Wang H, Fu HL, Li JN, et al. Comparison of whole-body ^18F-FDG SPECT and posttherapeutic ^131I scintigraphy in the detection of metastatic thyroid cancer[ J]. Clin Imaging, 2008, 32(1 ): 32- 37.
  • 3Ringel MD, Anderson J, Souza SL, et al. Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer[J]. Mod Pathol, 2001, 14(4) : 289 -296.
  • 4Grrard AC, Daumerie C, Mestdagh C, et al. Correlation between the loss of thyroglobulin iodination and the expression of thyroidspecific proteins involved in iodine metabolism in thyroid carcinomas [ J]. J Clin Endocrinol Metab, 2003, 88 (10) : 4977 - 4983.
  • 5Shimura H, Haraguchi K, Miyazaki A, et al. Iodide uptake and experimental ^131I therapy in transplanted undifferentiated thyroid cancer cells expressing the Na^+/I^- symporter gene [ J ]. Endocrinology, 1997, 138(10) : 4493 -4496.
  • 6Smit JW, Shroder-van der Elst JP, Karperien M, et al. Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a hNIS defective human thyroid carcinoma cell line [ J ]. Thyroid, 2000, 10 ( 11 ) : 939 - 943.
  • 7Coelho SM, Vaisman M, Carvalho DP. Tumour re-differentiation effect of retinoic acid: a novel therapeutic approach for advanced thyroid cancer[J]. Curr Pharm Des, 2005, 11 (19) : 2525 -2531.
  • 8Schmutzler C, Winzer R, Meissner-Weigl J, et al. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells[ J]. Biochem Biophys Res Commun, 1997, 240(3) : 832 -838.
  • 9Kebebew E, Peng M, Reiff E, et al. A phase Ⅱ trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negatine differentiated thyroid cancer[ J ]. Surgery, 2006, 140 ( 6 ) : 960 - 966.
  • 10Jarzab B, Handkiewiez-Junak D, Roskosz J, et al. Recombinant human TSH aided radioiedine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients [ J ]. Eur J Nucl Med Mol Imaging, 2003, 30(8) : 1077 -1086.

同被引文献32

  • 1叶智轶,傅宏亮,李佳宁,王辉.^(131)I-SPECT/CT融合显像对^(131)I全身显像在分化型甲状腺癌诊治中的增益价值[J].上海交通大学学报(医学版),2011,31(8):1150-1153. 被引量:2
  • 2傅烨生,郝慧钧,张德重,王忠明,耿强.131碘“清甲”治疗分化型甲状腺癌临床研究[J].中国血液流变学杂志,2014(1):153-156. 被引量:4
  • 3马建辉.重视实体瘤疗效评价标准的变革——RECIST概要[J].中华泌尿外科杂志,2006,27(2):77-79. 被引量:39
  • 4Yu GP, Li JC, Branovan D, et al. Thyroid cancer inci- dence and survival in the national cancer institute surveil- lance, epidemiology, and end results race/ethnicity groups [J]. Thyroid, 2010, 20(5): 465-473.
  • 5Podoloff DA, Ball DW, Ben-Josef E, et al. NCCN task force: clinical utility of PET in a variety of tumor types[J]. J Natl Compr Canc Netw, 2009, 7(Suppl 2):S1-S26.
  • 6Li W, Ain KB. Human sodium-iodide symporter (hNIS) gene expression is inhibited by a trans-active transcrip-tional repressor, NIS-repressor, containing PARP-1 in thy- roid cancer cells [J]. Endocr Relat Cancer, 2010, 17(2): 383-398.
  • 7Sodre AK, Rubio IG, Galrao AL, et al. Association of low sodium-iodide symporter messenger ribonucleic acid ex- pression in malignant thyroid nodules with increased in- tracellular protein staining [J]. J Clin Endocrinol Metab, 2008, 93(10): 4141-4145.
  • 8Smith VE, Read ML, Turnell AS, et al. A novel mecha- nism of sodium iodide symporter repression in differentiated thyroid cancer[J]. J Cell Sci, 2009, 122(Pt 18):3393-3402.
  • 9Foujilas C, Marakaki C, Sirmos N. Sodium-iodine sym- porter in thyroid, normal and cancer tissues and its rela- tion to nuclear medicine and to gene cloning treatment[J]. Hell J Nucl Med, 2009, 12(2):189-193.
  • 10Muhlbauer M, da Silva AC, Marassi MP, et al. Retinoic acid modulation of thyroid dual oxidase activity in rats and its impact on thyroid iodine organification [J]. J En- docrinol, 2010, 205(3):271-277.

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部